VIDEO – STOCKS AND PATIENTS GETTING HIGHER –  

July 1, 2022 – In today’s episode of PsycBiz, James —the Psychedelic Investor— sits down with Mark Haden, VP of Business Development for Clearmind Medicine (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0).

Clearmind is a next-gen psychedelics company working on treating addiction. Their main candidate is a next-gen psychedelic called MEAI. Currently, MEAI is being researched as a treatment for various forms of addiction, including Alcohol Use Disorder.

Though Clearmind’s MEAI is in its early stages, both pre-clinical results and anecdotal evidence suggests that it will be effective. The company plans to launch a phase 1 safety trial by the end of this year.

Mark Haden is a wonderful presenter, and I hope you enjoy this episode.

Before working with Clearmind, he worked at MAPS.

more@PsychedelicSpotlight

[ninja-popup ID=12216]